Background: The term juvenile idiopathic arthritis (JIA) describes a clinically heterogeneous group of arthritides. The onset in all subgroups is before 16 years of age, but each group presents with different clinical signs and symptoms. The cause of the disease is unknown, but both genetic and environmental factors are believed to be involved. Management of the disease has greatly improved in recent years due to advances in pharmacologic treatment options (especially with new biologic agents) and the prognosis for patients is better than ever before. However, none of the available drugs has a curative potential. This review provides an overview on the classification and the clinical symptoms of the defined subgroups of JIA as well as pharmacotherapies for it.
Conclusions: Treatment of children with JIA is challenging and complex. Since lengthy therapy might be necessary, a multidisciplinary pediatric rheumatology team is crucial for optimal treatment. Although a cure is unknown at this time, adequate treatment aims to preserve function of the joints as well as normal childhood development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000229757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Isolated Temporomandibular Arthritis as Presentation of Juvenile Idiopathic Arthritis.
J Craniofac Surg
January 2025
Rheumatology Unit, Department of Childhood and Developmental Medicine, ASST Fatebenefratelli-Sacco, Milano, MI.
Involvement of the temporomandibular joint (TMJ) in patients with juvenile idiopathic arthritis (JIA) has been increasingly reported, affecting up to 87% of cases. This involvement generally occurs after the diagnosis of JIA has been established; however, in the authors' cases, as in a few others documented in the literature, patients presented with isolated TMJ arthritis as the sole joint involvement. The authors performed a narrative literature review on TMJ involvement in JIA and reported 2 cases that presented with isolated TMJ arthritis as the initial manifestation of JIA.
View Article and Find Full Text PDFIntroduction: Anakinra has dramatically improved the management of systemic juvenile idiopathic arthritis (SJIA) over the last decade. Nevertheless, management remains inconsistent; corticosteroids are still frequently used. We analyzed the course of SJIA in children treated with anakinra according to the time of treatment initiation after disease onset.
View Article and Find Full Text PDF[Visualization analysis of research progress on work-related musculoskeletal disorders in domestic and international].
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
December 2024
Laboratony of Occupational Protation cool Ergonomics Chinese Center for Disease Control and Prevention, National Institute for Occupational Health and Poison Control, Beijing 100050, China.
To study aims to examine the current state and future trajectory of research on work-related musculoskeletal disorders (WMSDs) both domestically and internationally. In February 2024, Using CiteSpace software and bibliometrics, a bibliometric analysis and knowledge map study were conducted on the Web of Science core journal collection and 3144 related documents from CNKI as of December 31, 2023. This study included a total of 3144 articles (723 in Chinese and 2421 in English).
View Article and Find Full Text PDFAssessing cognitive functions in non-neuropsychiatric childhood systemic lupus erythematosus: Cross-sectional study.
J Psychosom Res
December 2024
Hacettepe University, Department of Pediatric Rheumatology, Ankara, Turkey.
Objectives: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by multisystem, including neuropsychiatric, involvement. The nervous system is affected in 20-27 % of patients within approximately two years after diagnosis. This study aimed to examine neurocognitive impairment in childhood-onset SLE (cSLE) patients before the development of any neurological, psychiatric, or cognitive manifestations.
View Article and Find Full Text PDFClinical implications of human Parvovirus B19 infection on autoimmunity and autoimmune diseases.
Int Immunopharmacol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan; Immunology Research Center, Chung Shan Medical University, Taichung 402, Taiwan. Electronic address:
Parvovirus B19 (B19V) is a human pathogen from the Parvoviridae family that primarily targets and replicates in erythroid progenitor cells (EPCs). While its symptoms are typically self-limiting in healthy individuals, B19V can cause or exacerbate autoimmune diseases in vulnerable patients. This review integrates the involvement of B19V in the development and worsening of several autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), hematological disorders (thalassemia, anemia, and thrombocytopenia), vasculitis, antiphospholipid syndrome (APS), dermatological disease (systemic sclerosis, psoriasis), autoimmune thyroid disease, myocarditis, and myasthenia gravis, and autoinflammatory disease of adult-onset Still's disease (AOSD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!